Amicus Therapeutics, Inc. (NASDAQ: FOLD) related to its sale to BioMarin Pharmaceutical Inc. Under the terms of the proposed transaction, Amicus shareholders are expected to receive $14.50 per share in cash.
Amicus Therapeutics, Inc. (NASDAQ: FOLD) related to its sale to BioMarin Pharmaceutical Inc. Under the terms of the proposed transaction, Amicus shareholders are expected to receive $14.50 per share in cash.